Clinical Trials Logo

Clinical Trial Summary

Extranodal natural killer/T-cell lymphoma, nasal type (NKTCL) is a highly aggressive peripheral T-cell lymphoma (PTCL). Patients with newly diagnosed stage IV and relapsed/refractory have poor prognosis. 5-year progression-free survival was reported only 55%. Chidamide is a selective histone deacetylase inhibitor which was approved by FDA in treating relapsed or refractory PTCL. In phase I and II studies of chidamide, patients with relapsed or refractory NKTCL achieved a higher overall remission. Patients who obtained complete or partial remission had much favourable duration of remission. Thus, the invesgator design this study to evaluate the role of maintenance treatment of chidamide for induction chemotherapy-responded newly-diagnosed advanced and relapsed/refractory NKTCL patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03630731
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Mei Dong
Phone 13811929322
Email dongmei030224@163.com
Status Recruiting
Phase Phase 2
Start date August 2018
Completion date March 2020

See also
  Status Clinical Trial Phase
Completed NCT05058755 - Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma N/A
Recruiting NCT06314334 - Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Phase 2
Completed NCT03618238 - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT04004572 - Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma Phase 2
Recruiting NCT03623087 - SIMPLE Chemotherapy for NK Lymphoma/Leukaemia Phase 3
Recruiting NCT03107962 - Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma Phase 2
Completed NCT03936452 - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma Phase 2
Recruiting NCT04366128 - Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL N/A
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2